Methods and compositions for the treatment of schizophrenia USING atypical antipsychotic combination therapy

摘要

1. figure (a) u043bu0435u0447u0435u043du0438u00a0 schizophrenia patient; (b) u0437u0430u043cu0435u0434u043bu0435u043du0438u00a0 progression of schizophrenia patients, who were diagnosed u0448u0438u0437u043eu0444u0440u0435u043du0438u00a0; or (c) prevention or u0437u0430u0434u0435u0440u0436 key u0440u0430u0437u0432u0438u0442u0438u00a0 schizophrenia patient, u0434u043bu00a0 which u0440u0430u0437u0432u0438u0442u0438u00a0 schizophrenia risk, including the introduction of the patient an effective amount of a combination thera s, including latrepirdine and u0430u0442u0438u043fu0438u0447u043du044bu0439 a serious antipsychotic.;2. method for 1, in which u043du0435u0439u0440u043eu043bu0435u043fu0442u0438u043au043eu043c u00a0u0432u043bu00a0u0435u0442u0441u00a0 risperidone.;3. method for 2, which u0440u0438u0441u043fu0435u0440u0438u0434u043eu043du0430 latrepirdine enhances therapeutic effect compared with the introduction of the u0440u0438u0441u043fu0435u0440u0438u0434u043eu043du0430 as resistance.;4. method for 1, in which u0432u0432u043eu0434u00a0u0442 in risperidone dose, less than u0442u0440u0435u0431u0443u0435u043cu0430u00a0 u0434u043bu00a0 u0440u0438u0441u043fu0435u0440u0438u0434u043eu043du0430 within individual / resistance u0434u043bu00a0 u043eu043au0430u0437u0430u043du0438u00a0 comparable u0442u0435u0440u0430u043fu0435u0432u0442u0438 the technical effect.;5. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 u043fu0440u0438u0435u043cu043bu0435u043cu0430u00a0 u043au043eu043cu043fu043eu0437u0438u0446u0438u00a0, u0432u043au043bu044eu0447u0430u044eu0449u0430u00a0 latrepirdine and u0430u0442u0438u043fu0438u0447u043du044bu0439 a serious antipsychotic.;6. u043au043eu043cu043fu043eu0437u0438u0446u0438u00a0 under clause 5, in which the u0430u0442u0438u043fu0438u0447u043du044bu043c u043du0435u0439u0440u043eu043bu0435u043fu0442u0438u043au043eu043c u00a0u0432u043bu00a0u0435u0442u0441u00a0 risperidone.;7. u043au043eu043cu043fu043eu0437u0438u0446u0438u00a0 for p.6, which u043du0430u0445u043eu0434u00a0u0442u0441u00a0 latrepirdine and risperidone in single drug form.;8. set, comprising: (a) latrepirdine; risperidone; (b) and (c) instructions for use in the treatment, prevention, delay of progression, or delay in the initiation and / or u0440u0430u0437u0432u0438u0442u0438u00a0 schizo u0444u0440u0435u043du0438u0438.;9. method u0443u0441u0438u043bu0435u043du0438u00a0 reaction a patient on u0430u0442u0438u043fu0438u0447u043du044bu0439 a serious antipsychotic, which includes the introduction of u0434u0438u043cu0435u0431u043eu043du0430 in combination with u0430u0442u0438u043fu0438u0447u043du044bu043c u043du0435u0439u0440u043eu043bu0435u043fu0442u0438u043au043eu043c, in which the patient has or has u043fu043eu0434u043eu0437u0440u0435u0432u0430u0435u0442u0441u00a0 u0448u0438u0437u043eu0444u0440u0435u043du0438u00a0.;10.method u043bu0435u0447u0435u043du0438u00a0 schizophrenia patient, including the patient combination therapy comprising latrepirdine and u0430u0442u0438u043fu0438u0447u043du044bu0439 a serious antipsychotic and combination therapy u0432u0432u043eu0434u00a0u0442 in an amount effective u0434u043bu00a0 u0443u043bu0443u0447u0448u0435u043du0438u00a0 cognitive symptoms of schizophrenia, and with u043au043eu043cu0431u0438u043du0438u0440u043eu0432u0430u043du043du0430u00a0 u0442u0435u0440u0430u043fu0438u00a0 leads to improve cognitive functions of the morethe use of u0430u0442u0438u043fu0438u0447u043du043eu0433u043e u043du0435u0439u0440u043eu043bu0435u043fu0442u0438u043au0430 as resistance.